- Home
- EVAX vs AWH Comparison
EVAX vs AWH Comparison
Compare EVAX & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- AWH
- Stock Information
- Founded
- EVAX 2008
- AWH 1993
- Country
- EVAX Denmark
- AWH United States
- Employees
- EVAX N/A
- AWH N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- AWH Medical/Dental Instruments
- Sector
- EVAX Health Care
- AWH Health Care
- Exchange
- EVAX Nasdaq
- AWH Nasdaq
- Market Cap
- EVAX 14.3M
- AWH 11.7M
- IPO Year
- EVAX 2021
- AWH N/A
- Fundamental
- Price
- EVAX $1.37
- AWH $0.73
- Analyst Decision
- EVAX Strong Buy
- AWH Buy
- Analyst Count
- EVAX 2
- AWH 2
- Target Price
- EVAX $11.00
- AWH $4.40
- AVG Volume (30 Days)
- EVAX 40.9K
- AWH 82.8K
- Earning Date
- EVAX 10-31-2024
- AWH 11-14-2024
- Dividend Yield
- EVAX N/A
- AWH N/A
- EPS Growth
- EVAX N/A
- AWH N/A
- EPS
- EVAX N/A
- AWH N/A
- Revenue
- EVAX $3,295,000.00
- AWH $8,963,000.00
- Revenue This Year
- EVAX $4,845.21
- AWH $15.56
- Revenue Next Year
- EVAX $30.30
- AWH $105.32
- P/E Ratio
- EVAX N/A
- AWH N/A
- Revenue Growth
- EVAX N/A
- AWH N/A
- 52 Week Low
- EVAX $1.28
- AWH $0.67
- 52 Week High
- EVAX $13.61
- AWH $5.65
- Technical
- Relative Strength Index (RSI)
- EVAX 22.79
- AWH 33.65
- Support Level
- EVAX $1.28
- AWH $0.67
- Resistance Level
- EVAX $1.80
- AWH $0.87
- Average True Range (ATR)
- EVAX 0.27
- AWH 0.08
- MACD
- EVAX -0.10
- AWH -0.02
- Stochastic Oscillator
- EVAX 6.08
- AWH 22.22
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.